ABSTRACT
Effects of Morus alba-leaf extracts on glycemic control and blood lipids were carried out in 27 patients with newly diagnosed type 2 diabetes. Water extracts of Morus alba leaves at a dosage of 700 mg were given to the patients thrice daily for 8 weeks. The patients did not receive any concomitant medications for diabetes or hyperlipidemia. The mean fasting plasma glucose levels at baseline, week 2, week 4, week 6 and week 8 were 155.1, 179, 173.6, 183.9 and 185.8 mg/dl, respectively (p=0.04). The mean glycosylated hemoglobin levels at baseline and week 8 were 7.6% and 8.4%, respectively (p=0.002). The mean blood total cholesterol levels at baseline, week 2, week 4, week 6 and week 8 were 229.6, 211.2, 210.2, 204.5 and 199.4 mg/dl, respectively (p<0.001). The mean blood triglyceride levels at baseline, week 2, week 4, week 6 and week 8 were 235.4, 191.3, 174.5, 183.5 and 168.2 mg/dl, respectively (p=0.001). No patients experienced side effects of the treatment. Laboratory results on CBC, urine, blood electrolytes, renal function and liver function at baseline, week 2, week 4, week 6 and week 8 were not significantly different. Morus alba-leaf extracts have no hypoglycemic effect but they exert lipid lowering effects.
ABSTRACT
A randomized double blind placebo controlled trial was conducted to determine the efficacy of Gymnostemma pentaphyllum in patients with hyperlipidemia. Twenty-three patients were allocated to receive Gymnostemma pentaphyllum powder in capsule at the dosage of 5 grams thrice a day for 3 months. Twenty-one patients received placebo in identical capsules thrice a day for 3 months. Lipid profiles (cholesterol, triglyceride, high density lipoprotein and low density lipoprotein) were determined prior to taking medication and every month thereafter. Lipid profiles of all patients at entry were not significantly different from those after therapy. Lipid profiles of the patients in both groups at month 1, 2 and 3 were not significantly different. Oxidative stress & anti-oxidant activity and anti-platelet activity in the serum samples taken from patients in both groups were not significantly different. Adverse events and abnormal laboratory tests were not observed in patients receiving Gymnostemma pentaphyllum. Most of the patients were satisfied with the treatment they received. It is concluded that Gymnostemma pentaphyllum powder in capsules prepared by Department of Medical Sciences, Ministry of Public Health at the dosage of 5 grams thrice a day for 3 months is safe but not efficacious in reducing lipids in patients with hyperlipidemia.